Loading...

CLEARSIDE BIOMEDICAL INC Operational Disruptions 8-K Filing

CLRS

CLEARSIDE BIOMEDICAL INC

()

2023 8-K

Bankruptcy Filing Update

Delisting Notification

Bankruptcy Filing

Compliance Regained

Stock Split Announcement

Stock Split Announced

Amendment Agreement

Listing Compliance Notice

Delisting Notice

Management Changes

Financial Statements

Financial Results

Nasdaq Compliance Notice

Corporate Presentation

Financial Results

Positive Trial Results

Financial Results

Webinar Presentation

Annual Meeting of Stockholders

Appointment of Director

Registered Direct Offering

Amendment to License Agreement

Agreement Amendment

License Agreement with BioC...

Earnings Reports

Equity Offering

Clinical Trial Announcement

Earnings Reports

Resignation and Appointment

Resignation of Officer

Results of OASIS Extension ...

External Links:

Clearside Biomedical announced plans for a Phase 2b clinical trial of CLS-AX for wet AMD, with enrollment starting in Q2 2023 and results expected in Q3 2024.

AI Assistant

CLEARSIDE BIOMEDICAL INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.